This protocol addresses MEN2A in the specific setting of metastatic medullary thyroid carcinoma complicated by Cushing's syndrome arising from ectopic ACTH or CRH production — a presentation that significantly shapes treatment priorities.
Patients with metastatic MTC who develop Cushing's syndrome due to ectopic ACTH or CRH production are often markedly debilitated. Despite a poor prognosis, active treatment is indicated, with control of hypercortisolism as a central clinical concern.
Management centres on medical therapy directed at hypercortisolism. The full selection of agents, their sequencing, and the complete regimen are detailed in the structured protocol.
Complete evidence-based regimen available via the link below.
DOI: 10.1089/thy.2014.0335
Patients with metastatic MTC and Cushing's syndrome due to ectopic production of ACTH or CRH are often markedly debilitated and should be treated despite their poor prognosis.
Treatment options include medical therapy with ketoconazole, mifepristone, aminoglutethimide, metyrapone, or mitotane.
View source ↗